← back to search

Bart Jan Kullberg

Radboud University Nijmegen · NL
Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Antifungal resistance and susceptibility, Fungal Infections and Studies, Immune Response and Inflammation, and Vector-borne infectious diseases.
h-index
108
citations
54,394
works
470
NIH funding
primary concept
Medicine
email

Recent publications

Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM
Intensive Care Medicine 2024cited by 160position: middledoi
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials
Critical Care 2024cited by 16position: middledoi
Treatment Outcomes Among Patients With a Positive<i>Candida</i>Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study
Clinical Infectious Diseases 2024cited by 8position: middledoi
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials
The Lancet Infectious Diseases 2023cited by 70position: middledoi
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
The Lancet 2022cited by 165position: middledoi
Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study
Infectious Diseases and Therapy 2022cited by 51position: middledoi
EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group
Clinical Infectious Diseases 2021cited by 284position: middledoi
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion
Intensive Care Medicine 2020cited by 442position: middledoi
Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline
Clinical Microbiology and Infection 2020cited by 207position: middledoi
147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
Open Forum Infectious Diseases 2020cited by 17position: middledoi
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
Clinical Infectious Diseases 2019cited by 2,757position: middledoi
Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project
Critical Care 2019cited by 249position: middledoi
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Clinical Microbiology and Infection 2018cited by 1,502position: middledoi
Invasive candidiasis
Nature Reviews Disease Primers 2018cited by 1,461position: lastdoi
Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial
Clinical Infectious Diseases 2018cited by 178position: firstdoi
Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp>gal infections Definitions in <scp>ICU</scp> patients (<scp>FUNDICU</scp>) project
Mycoses 2018cited by 61position: middledoi
Intensive care medicine research agenda on invasive fungal infection in critically ill patients
Intensive Care Medicine 2017cited by 186position: middledoi
International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus
Drug Resistance Updates 2015cited by 328position: middledoi
Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia
Nature Communications 2014cited by 80position: middledoi
Role of autophagy genetic variants for the risk of Candida infections
Medical Mycology 2014cited by 18position: middledoi
Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans
Nature Communications 2013cited by 215position: middledoi
Autophagy is redundant for the host defense against systemic Candida albicans infections
European Journal of Clinical Microbiology & Infectious Diseases 2013cited by 40position: middledoi
Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of Monocytes
Cell Host & Microbe 2012cited by 1,238position: middledoi
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
Clinical Microbiology and Infection 2012cited by 1,211position: middledoi
Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials
Clinical Infectious Diseases 2012cited by 794position: middledoi
ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures
Clinical Microbiology and Infection 2012cited by 394position: middledoi
ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.
Clinical Microbiology and Infection 2012cited by 360position: middledoi
ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)
Clinical Microbiology and Infection 2012cited by 335position: middledoi
Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia
The Journal of Infectious Diseases 2012cited by 137position: middledoi
Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis
Journal of Clinical Microbiology 2012cited by 95position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Oliver A. Cornely · Agostino Gemelli University Polyclinic9 papers (2012–2024)Mihai G. Netea · Eindhoven University of Technology8 papers (2012–2014)Matteo Bassetti · Istituto Nazionale di Fisica Nucleare, Sezione di Genova8 papers (2012–2024)Claudio Viscoli · University of Lausanne7 papers (2012–2018)Leo A. B. Joosten · German Center for Neurodegenerative Diseases7 papers (2012–2014)Maiken Cavling Arendrup · Statens Serum Institut6 papers (2012–2018)José A. Vázquez · Augusta University6 papers (2018–2024)John R. Perfect · Duke University6 papers (2012–2014)Peter G. Pappas · University of Alabama at Birmingham6 papers (2012–2024)J.W.M. van der Meer · Radboud University Nijmegen6 papers (2012–2014) · 6 papers (2012–2014) · 6 papers (2012–2014)Raoul Herbrecht · Amgen (United States)6 papers (2012–2018)William K. Scott · University of Miami5 papers (2012–2014)Thierry Calandra · University of Lausanne5 papers (2012–2021)Andreas H. Groll · TU Dortmund University5 papers (2012–2015)Paul E. Verweij · Radboud University Nijmegen5 papers (2012–2015)Olivier Lortholary · Institut Pasteur5 papers (2012–2012)J. Peter Donnelly · Baylor College of Medicine5 papers (2012–2015)Jacques Billé · University of Lausanne4 papers (2012–2012)